학술논문
A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer
Document Type
Article
Author
Source
In: Gynecologic Oncology . (Gynecologic Oncology, February 2021, 160(2):418-426)
Subject
Language
English
ISSN
10956859
00908258
00908258